COMMUNIQUÉS West-GlobeNewswire

UroGen Pharma to Present at Upcoming Investor Conferences
07/05/2026
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
07/05/2026
Renewed agreement provides streamlined access to ENvue equipment and supplies across a network of more than 90 hospitals in 17 states TYLER, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc . (NASDAQ: FEED) (“ [...]
MediWound to Report First Quarter 2026 Financial Results
07/05/2026
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global [...]
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
07/05/2026
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant [...]
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
07/05/2026
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in [...]
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
07/05/2026
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental [...]
InStride Health Sustains Outstanding Clinical Results in Third Annual Outcomes Report; Announces State Expansion Across East Coast
07/05/2026
97% of InStride patients demonstrate clinical improvement as company nearly doubled patient enrollment in 2025 ahead of continued state expansion BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- InStride Health , the leader in [...]
vTv Therapeutics to Participate in Upcoming May Investor Conferences
07/05/2026
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral [...]
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
07/05/2026
Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment Financing also drives early- and [...]
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
07/05/2026
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world [...]
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
07/05/2026
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 [...]
Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
07/05/2026
ROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments, today provided an update on the expansion of its CompuFlo® medical [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
07/05/2026
Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospital, three HOPE [...]
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
07/05/2026
Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE [...]
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
07/05/2026
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis [...]
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
07/05/2026
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Phase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, [...]
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
07/05/2026
ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 [...]
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
07/05/2026
– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confirmed QRX003 [...]
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
07/05/2026
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved therapies [...]

Pages